Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 3NETWORK 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Osteoporosis 2Breast Neoplasms 2Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 39Docetaxel 30Tamoxifen 29Paclitaxel 27Doxorubicin 26Trastuzumab 20Radiotherapy 18Epirubicin 16Letrozole 13exemestane 11Fluorouracil 11Anastrozole 11Capecitabine 10Bevacizumab 10Immunohistochemistry 9Filgrastim 9Fulvestrant 8Methotrexate 7Gene Expression Profiling 7palbociclib 6Zoledronic Acid 6Microarray Analysis 6Lapatinib 6Goserelin 6Chemotherapy, Adjuvant 6Amplified Fragment Length Polymorphism Analysis 6Vinorelbine 5Triptorelin Pamoate 5Carboplatin 5Absorptiometry, Photon 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Breast Neoplasms × Risedronic Acid × Clear all
NCT00354302 2020-04-02

Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial

Canadian Cancer Trials Group

Phase 3 Completed
497 enrolled
Breast

Breast Neoplasms, Osteoporosis

NCT00324714 2012-11-29

Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCIS

ETOP IBCSG Partners Foundation

Phase 3 Withdrawn
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Osteoporosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡